As of November 6, 2026, Aurinia Pharmaceuticals Inc. is a publicly traded company (Nasdaq: AUPH). The largest holder reporting an active stake on Schedule 13D is Tang Capital Management, LLC, at 10%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, June 4, 2026).
Is this your company?
About to sign with, pay or invest in Aurinia Pharmaceuticals Inc.? See the free Snapshot first.
Free to see. No signup.
Is Aurinia Pharmaceuticals Inc. a real, registered company?
- Aurinia Pharmaceuticals Inc. files with the SEC under CIK 1600620 (its SEC filings).
- Its shares are listed under the ticker AUPH on Nasdaq (SEC company record).
- business address in Edmonton, A0, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Aurinia Pharmaceuticals Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Tang Capital Management, LLC (filed 2026-06-04).
Who are Aurinia Pharmaceuticals Inc.'s owners and officers?
Aurinia Pharmaceuticals Inc.: business address in Edmonton, A0; industry Pharmaceutical Preparations (Schedule 13D/A, 2026-08-26).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-08-26 | Iljin Snt Co., LTD. | 4.4% |
| Schedule 13D/A, 2026-06-04 | Tang Capital Management, LLC | 10% |
| Schedule 13D/A, 2026-03-25 | Tang Capital Management, LLC | 9.2% |
| Schedule 13D/A, 2026-03-03 | Tang Capital Management, LLC | 9.2% |
| Schedule 13D/A, 2025-08-13 | Iljin Snt Co., LTD. | 5% |
Questions about who owns Aurinia Pharmaceuticals Inc.
Who owns Aurinia Pharmaceuticals Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Aurinia Pharmaceuticals Inc.: Tang Capital Management, LLC (10%, Schedule 13D/A, filed 2026-06-04).
When did Tang Capital Management, LLC buy into Aurinia Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Tang Capital Management, LLC on this page is the Schedule 13D/A, filed 2026-03-03, reporting 9.2%; its latest, Schedule 13D/A filed 2026-06-04, reports 10%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Aurinia Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Aurinia Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aurinia Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Aurinia Pharmaceuticals Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Tang Capital Management LLC, a 10% owner: 13,044,106 shares (9.7% of shares outstanding), held indirectly through By LP, on a joint filing (Form 4, 2026-06-02).
- , the chief executive and a director: 13,044,106 shares (9.7% of shares outstanding), held indirectly through By LP, on a joint filing (Form 4, 2026-06-02).
- , the chief executive and a director: 1,840,379 shares (1.4% of shares outstanding) (Form 4, 2026-03-03).
- , the chief operating officer: 680,299 shares (0.51% of shares outstanding) (Form 4, 2026-03-03).
- , the chief legal officer: 588,848 shares (0.44% of shares outstanding) (Form 4, 2026-09-11).
Shares outstanding: 133,998,660 as of 2026-10-29, from the company's latest SEC cover page.
How much has Aurinia Pharmaceuticals Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-05-11).
Keep reading
More on Aurinia Pharmaceuticals Inc. and the records around it.
Aurinia Pharmaceuticals Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/aurinia-pharmaceuticals